[Federal Register Volume 64, Number 8 (Wednesday, January 13, 1999)]
[Notices]
[Pages 2227-2228]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 99-740]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration


Vaccines and Related Biological Products Advisory Committee; 
Notice of Meeting

AGENCY:  Food and Drug Administration, HHS.

ACTION:  Notice.

-----------------------------------------------------------------------

    This notice announces a forthcoming meeting of a public advisory 
committee of the Food and Drug Administration (FDA). At least one 
portion of the meeting will be closed to the public.
    Name of Committee: Vaccines and Related Biological Products 
Advisory Committee.
    General Function of the Committee: To provide advice and 
recommendations to the agency on FDA's regulatory issues.
    Date and Time: The meeting will be held on January 29, 1999, 8:30 
a.m. to 6:30 p.m.
    Location: Holiday Inn, Versailles Ballrooms III and IV, 8120 
Wisconsin Ave., Bethesda, MD.
    Contact Person: Nancy T. Cherry or Denise H. Royster, Center for 
Biologics Evaluation and Research (HFM-71), Food and Drug 
Administration, 1401 Rockville Pike, Rockville, MD 20852, 301-827-0314, 
or FDA Advisory Committee Information Line, 1-800-741-8138 (301-443-
0572 in the Washington, DC area), code 12391. Please call the 
Information Line for up-to-date information on this meeting.
    Agenda: The committee will: (1) Discuss the influenza virus vaccine 
formulation for 1999 and 2000, and (2) hear an update on the status of 
influenza A H5N1 viruses.
    Procedure: On January 29, 1999, from 8:30 a.m. to 5:30 p.m., the 
meeting is open to the public. Interested persons may present data, 
information, or views, orally or in writing, on issues pending before 
the committee. Written submissions may be made to the contact person by 
January 22, 1999. Oral

[[Page 2228]]

presentations from the public will be scheduled between approximately 
8:45 a.m. and 9:15 a.m., and between 3:30 p.m. and 4 p.m. Time allotted 
for each presentation may be limited. Those desiring to make formal 
oral presentations should notify the contact person before January 22, 
1999, and submit a brief statement of the general nature of the 
evidence or arguments they wish to present, the names and addresses of 
proposed participants, and an indication of the approximate time 
requested to make their presentation.
    Closed Committee Deliberations: On January 29, 1999, from 5:30 p.m. 
to 6:30 p.m., the meeting will be closed to permit discussion and 
review of trade secret and/or confidential information (5 U.S.C. 
552b(c)(4)). This portion of the meeting will be closed to discuss 
issues relating to pending or proposed investigational new drug 
applications.
    Notice of this meeting is given under the Federal Advisory 
Committee Act (5 U.S.C. app. 2).
    Dated: January 7, 1999.
Michael A. Friedman,
Deputy Commissioner for Operations.
[FR Doc. 99-740 Filed 1-12-99; 8:45 am]
BILLING CODE 4160-01-F